Recap: Intra-Cellular Therapies Q3 Earnings

Comments
Loading...

Intra-Cellular Therapies ITCI reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Earnings

Intra-Cellular Therapies beat estimated earnings by 29.63%, reporting an EPS of $-0.57 versus an estimate of $-0.81.

Revenue was up $49.66 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.16 which was followed by a 5.08% increase in the share price the next day.

Here's a look at Intra-Cellular Therapies's past performance:

 

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate -0.76 -0.92 -1 -0.92
EPS Actual -0.92 -0.78 -1.05 -0.95
Revenue Estimate 49.02M 33.65M 25.37M 22.12M
Revenue Actual 55.58M 35.00M 25.67M 22.21M

To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!